Table 2.
Clinical trials with modulators of chemokine functions within the tumor microenvironment.
| Name | Mode of action | Clinical trial | Current status |
|---|---|---|---|
| CHEMOKINE RECEPTOR ANTAGONISM | |||
| Reparixin | CXCR 1/2 inhibition | Phase IB (NCT02001974) |
- Completed: 30% response rate in patients with metastatic breast cancer, well tolerated (42) - Combined with chemotherapy (paclitaxel) |
| AZD5069 | Phase I/ II (NCT03177187) |
- Recruiting patients with metastatic castrate-resistant prostate cancer - Combined with antiandrogen medication (enzalutamide) |
|
| SX-682 | Phase I (NCT03161431) |
- Recruiting patients with metastatic melanoma - Combined with immune checkpoint inhibitor (pembrolizumab) |
|
| AMD3100 (Plerixafor) | CXCL12/CXCR4 inhibition | Phase I (NCT03277209) |
- Recruiting patients with pancreatic, ovarian and colorectal adenocarcinomas - Assess safety and impact on TME |
| NCT02695966 | - Ex-Vivo assessment of T lymphocyte function and localization in pancreatic cancer | ||
| Ulocuplumab (BMS-936564) | Phase I/II (NCT02472977) |
- In combination with nivolumab - Terminated due to lack of efficacy |
|
| LY2510924 | Phase II (NCT01439568) |
- In combination with carboplatin and etoposide - No clinical benefit in patients with extensive-disease small cell lung carcinoma (43) |
|
| Phase II (NCT01391130) |
- In combination with sunitinib - Terminated due to insufficient efficacy in patients with metastatic clear cell renal cell carcinoma |
||
| Phase 1 (NCT02737072) |
- In combination with durvulumab for patients with advanced solid tumors - Terminated |
||
| USL 311 | Phase I / II NCT02765165 | - Recruiting patients with glioblastoma multiforme | |
| Olaptesed (NOX-A12) | Phase I/II (NCT03168139) |
- Olaptesed in combination with pembrolizumab - Recruiting patients with colorectal and pancreatic cancer |
|
| GENETICALLY MODIFIED EFFECTOR IMMUNE CELLS | |||
| CXCR2 + NGFR + T cells | Phase I/ II (NCT01740557) |
- Recruiting patients with metastatic melanoma | |